Puma Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Puma BiotechnologyDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 1.9% bzw. 37.8% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-37.8%

Wachstumsrate der Gewinne

-37.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	-1.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PBYI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	230	16	43	53	2
12/31/2025	225	15	47	44	2
12/31/2024	219	10	45	24	2
3/31/2024	227	15	35	36	N/A
12/31/2023	236	22	14	27	N/A
9/30/2023	229	4	5	24	N/A
6/30/2023	230	-2	11	31	N/A
3/31/2023	235	5	-6	14	N/A
12/31/2022	228	0	-23	-16	N/A
9/30/2022	218	10	-29	-29	N/A
6/30/2022	207	-34	-36	-36	N/A
3/31/2022	201	-49	-22	-22	N/A
12/31/2021	253	-29	21	21	N/A
9/30/2021	250	-48	20	20	N/A
6/30/2021	255	-35	12	12	N/A
3/31/2021	272	-27	18	28	N/A
12/31/2020	225	-60	-9	1	N/A
9/30/2020	235	-56	-2	8	N/A
6/30/2020	241	-42	-11	-1	N/A
3/31/2020	224	-82	27	27	N/A
12/31/2019	272	-76	22	22	N/A
9/30/2019	280	-95	28	28	N/A
6/30/2019	287	-92	28	28	N/A
3/31/2019	284	-99	-35	-34	N/A
12/31/2018	251	-114	-25	-24	N/A
9/30/2018	202	-147	-117	-67	N/A
6/30/2018	145	-210	-165	-114	N/A
3/31/2018	94	-243	-193	-143	N/A
12/31/2017	28	-292	N/A	-172	N/A
9/30/2017	6	-301	N/A	-178	N/A
6/30/2017	N/A	-289	N/A	-158	N/A
3/31/2017	N/A	-278	N/A	-143	N/A
12/31/2016	N/A	-276	N/A	-142	N/A
9/30/2016	N/A	-265	N/A	-134	N/A
6/30/2016	N/A	-260	N/A	-136	N/A
3/31/2016	N/A	-258	N/A	-139	N/A
12/31/2015	N/A	-239	N/A	-154	N/A
9/30/2015	N/A	-225	N/A	-140	N/A
6/30/2015	N/A	-200	N/A	-127	N/A
3/31/2015	N/A	-175	N/A	-110	N/A
12/31/2014	N/A	-142	N/A	-77	N/A
9/30/2014	N/A	-110	N/A	-72	N/A
6/30/2014	N/A	-89	N/A	-60	N/A
3/31/2014	N/A	-63	N/A	-54	N/A
12/31/2013	N/A	-55	N/A	-55	N/A
9/30/2013	N/A	-61	N/A	-66	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PBYIFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-37.8% pro Jahr).

Ertrag vs. Markt: PBYIFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-37.8% pro Jahr).

Hohe Wachstumserträge: PBYIFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: PBYIDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-1.9% pro Jahr).

Hohe Wachstumseinnahmen: PBYIDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-1.9% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PBYI in 3 Jahren voraussichtlich hoch sein wird

Puma Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Consensus EPS estimates increase by 45%, revenue downgraded

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Consensus EPS estimates increase by 32%, revenue downgraded

Recent updates

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)

Investor sentiment deteriorates as stock falls 20%

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Puma Biotechnology, Inc., Annual General Meeting, Jun 18, 2024

Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 15%

Consensus EPS estimates increase by 45%, revenue downgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Founder notifies of intention to sell stock

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment improves as stock rises 15%

Independent Director recently sold US$71k worth of stock

Independent Director notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 32%, revenue downgraded

Investor sentiment improves as stock rises 17%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Consensus EPS estimates increase by 240%

Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021)

Puma Biotechnology, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Puma Biotechnology, Inc.’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

Founder recently sold US$114k worth of stock

Founder notifies of intention to sell stock

Investor sentiment deteriorated over the past week

Puma Biotechnology, Inc. announced that it has received $2.499996 million in funding

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium

Investor sentiment improved over the past week

Price target decreased to US$5.40

Puma Biotechnology, Inc. Announces Update on Defamation Lawsuit

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Consensus forecasts updated